North America Breast Cancer Therapeutics Market Forecast to 2030
North America Breast Cancer Therapeutics Market Forecast to 2030 – Regional Analysis – by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapy), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/ Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Pharmacies)
$2,840 – $4,440
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Use of Personalized Medicine Fuels the North America Breast Cancer Therapeutics Market
Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.
By providing tailored treatments to individual patients, healthcare providers can increase the likelihood of successful outcomes and reduce the risk of unnecessary side effects. In addition to improving patient outcomes, personalized medicine also offers economic benefits. By selecting treatments that are more likely to be effective, healthcare providers can reduce healthcare costs associated with ineffective treatments and avoid unnecessary expenses. As advancements in genomics and molecular diagnostics progress, personalized medicine is likely to become increasingly accessible and integrated into standard treatment protocols in the coming years. Therefore, the increasing use of personalized medicine is anticipated to bring new growth trends in the North America breast cancer therapeutics market.
North America Breast Cancer Therapeutics Market Overview
The breast cancer therapeutics market in North America is segmented into the US, Canada, and Mexico; the US holds the largest market share in this region. The market growth is mainly attributed to the region, which is expected to witness consistent growth owing to factors such as the rising prevalence of breast cancer and rising R&D investments for developing novel treatments. In addition, a growing number of market players are expanding their geographical footprint in North American countries.
Improvements in medical technology and research have sparked the creation of ground-breaking treatments that can enhance patient outcomes. Several large pharmaceutical companies, including Pfizer, Novartis, Roche, AstraZeneca, and Eli Lilly, dominate the therapeutic market for breast cancer in the US. These businesses make significant investments in research and development to introduce novel and enhanced medicines to the market. Regulations and policies put in place by the government also affect the market. New medications and therapies for breast cancer treatment are approved by the government agencies of the Food and Drug Administration (FDA). In the upcoming years, the therapeutic market for breast cancer is anticipated to expand further.
North America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
North America Breast Cancer Therapeutics Market Segmentation
The North America breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the North America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the North America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the North America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the North America breast cancer therapeutics market is categorized into US, Canada, and Mexico. The US dominated the North America breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the North America breast cancer therapeutics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the North America breast cancer therapeutics market was valued at US$ 13,346.87 million in 2022 and is expected to reach US$ 27,014.92 million by 2030, registering a CAGR of 9.2% from 2022 to 2030. Growing burden of breast cancer and launch of several diagnostics and screening programs are among the critical factors attributed to the North America breast cancer therapeutics market expansion.
Breast cancer is considered the most common cancer among women worldwide, and its incidence is increasing globally. Factors such as lifestyle changes, hormonal imbalances, genetic predisposition, and environmental factors contribute to the rising prevalence of breast cancer. According to WHO, in 2020, 685,000 people died worldwide from breast cancer, accounting for 2.3 million new diagnoses. Breast cancer is one of the most common cancers globally, with 7.8 million women alive as of the end of 2020 who had received a diagnosis within the previous five years. All across the world, breast cancer affects women at any age after adolescence. However, its prevalence rises with age.
Per the American Cancer Society, approximately 5-10% of all malignancies are caused by genes inherited from parents. Several cancer-predisposition genes have been discovered. For instance, mutations in the inherited cancer predisposition genes BRCA1 and BRCA2 raise the risk of getting certain malignancies, such as breast, ovarian, and prostate cancer.
Furthermore, breast cancer is one of the most common types of cancer in the US. A report published by Breastcancer.org in January 2022 stated that 1 in 8 women in the nation (or ~13%) will acquire invasive breast cancer over their lifetime. According to the same source, 287,850 new incidences of invasive breast cancer, along with 51,400 new cases of noninvasive (in situ) breast cancer, are anticipated to be detected in women in the US in 2022. In the same year, the country is anticipated to record ~2,710 additional cases of invasive breast cancer in men. Approximately 1 in 833 men might develop breast cancer in their lives. With the rise in breast cancer cases, there is an increasing need for effective and targeted therapies to improve patient outcomes. This has led to a surge in research and development activities in breast cancer therapeutics. Therefore, the growing burden of breast cancer drives the North America breast cancer therapeutics market.
On the contrary, high cost of diagnosis and treatment hampers the growth North America breast cancer therapeutics market.
Based on drug therapy, the North America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 62.5% share of the North America breast cancer therapeutics market in 2022, amassing US$ 8,343.01 million. It is projected to garner US$ 17,427.64 million by 2030 to expand at 9.6% CAGR during 2022-2030. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the North America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 63.4% share of the North America breast cancer therapeutics market in 2022, amassing US$ 8,461.94 million. It is projected to garner US$ 17,652.90 million by 2030 to expand at 9.6% CAGR during 2022-2030.
By distribution channel, the North America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 70.2% share of North America breast cancer therapeutics market in 2022, amassing US$ 9,367.08 million. It is projected to garner US$ 19,326.80 million by 2030 to expand at 9.5% CAGR during 2022-2030.
Based on country, the North America breast cancer therapeutics market is categorized into US, Canada, and Mexico. The US held 83.6% share of North America breast cancer therapeutics market in 2022, amassing US$ 11,159.40 million. It is projected to garner US$ 23,043.37 million by 2030 to expand at 9.5% CAGR during 2022-2030.
Key players operating in the North America breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc, among others.
– In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreements terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.
– In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in North America breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Breast Cancer Therapeutics Market – Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market – North America Market Analysis
5.1 North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
6. North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Drug Therapy
6.1 Overview
6.2 North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Breast Cancer Type
7.1 Overview
7.2 North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Breast Cancer Therapeutics Market – Regional Analysis
9.1 North America Breast Cancer Therapeutics Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 North America Breast Cancer Therapeutics Market, Breakdown, by Country, Revenue (2022) (US$ Million)
9.1.3 North America Breast Cancer Therapeutics Market, by Country
9.1.3.1 US
9.1.3.1.1 US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 US: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 US: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 US: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 US: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 US: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Canada
9.1.3.2.1 Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Canada: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Canada: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Canada: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Canada: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Canada: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 Mexico
9.1.3.3.1 Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 Mexico: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 Mexico: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 Mexico: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 Mexico: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 Mexico: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Amgen Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Breast Cancer Therapeutics Market Segmentation
Table 2. North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 4. US Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 5. US Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 6. US Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. US Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 21. Glossary of Terms, Breast Cancer Therapeutics Market
LIST OF FIGURES
Figure 1. North America Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. North America Breast Cancer Therapeutics Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: North America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Breast Cancer Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 19. North America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Growth Strategies in Breast Cancer Therapeutics Market
The List of Companies – North America Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Genentech Inc
9. Teva Pharmaceutical Industries Ltd
10. Amgen Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.